Drug intelligence / Profile preview

MNE-CXX3

Development stage: Preclinical
Lead developer: myNEO Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

MNE-CXX3 is an off-the-shelf mRNA-based cancer vaccine being developed by myNEO Therapeutics for the treatment of pancreatic adenocarcinoma (PAAD). The vaccine utilizes the company's proprietary Camyotopes platform, which identifies shared neoantigens (neoepitopes) that are frequently present in specific patient populations but absent in healthy tissue. By delivering mRNA encoding these tumor-associated neoantigens, MNE-CXX3 aims to stimulate a robust and specific T-cell-mediated immune response against pancreatic tumor cells. The program is currently in the preclinical stage of development.

Targets

NeoAg-MHC (Tumor neoantigen peptides presented on MHC class I and II)

Beyond the preview

Go deeper on MNE-CXX3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNE-CXX3.

Explore the full profile